22. Hardingham TE, Fosang AJ, Dudhia J (1994) The structure, function and turnover of
aggrecan, the large aggregating proteoglycan from cartilage. Eur J Clin Chem Clin Biochem
32:249–257
23. Yin M, Ding K, Gropeanu RA et al (2008) Dendritic star polymers for efficient DNA binding
and stimulus-dependent DNA release. Biomacromolecules 9:3231–3238. doi:10.1021/
bm800797j
24. Ng JF, Jaenicke S, Eisele K et al (2010) cBSA-147 for the preparation of bacterial biofilms in
a microchannel reactor. Biointerphases 5:FA41–FA47. doi:10.1116/1.3474475
25. Ritz S, Eisele K, Dorn J et al (2010) Cationized albumin-biocoatings for the immobilization
of lipid vesicles. Biointerphases 5:FA78–FA87. doi:10.1116/1.3494039
26. Ng JF, Weil T, Jaenicke S (2011) Cationized bovine serum albumin with pendant RGD
groups forms efficient biocoatings for cell adhesion. J Biomed Mater Res B Appl Biomater
99:282–290. doi:10.1002/jbm.b.31897
27. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer
chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent
smancs. Cancer Res 46:6387–6392
28. Kratz F (2002) Drug conjugates with albumin and transferrin. Expert Opin Ther Pat
12:433–439. doi:10.1517/13543776.12.3.433
29. Maeda H (2001) The enhanced permeability and retention (EPR) effect in tumor vasculature:
the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul
41:189–207
30. Elsadek B, Kratz F (2012) Impact of albumin on drug delivery – new applications on the
horizon. J Control Release 157:4–28. doi:10.1016/j.jconrel.2011.09.069
31. Neumann E, Frei E, Funk D et al (2010) Native albumin for targeted drug delivery. Expert
Opin Drug Deliv 7:915–925. doi:10.1517/17425247.2010.498474
32. Varshney A, Sen P, Ahmad E et al (2010) Ligand binding strategies of human serum albumin:
how can the cargo be utilized? Chirality 22:77–87. doi:10.1002/chir.20709
33. Paa ´l K, Mu ¨ller J, Hegedu ˆs L (2001) High affinity binding of paclitaxel to human serum
albumin. Eur J Biochem 268:2187–2191
34. Xu R, Fisher M, Juliano RL (2011) Targeted albumin-based nanoparticles for delivery of
amphipathic drugs. Bioconjug Chem 22:870–878. doi:10.1021/bc1002295
35. Sun H-H, Zhang J, Zhang Y-Z et al (2012) Interaction of human serum albumin with
10-hydroxycamptothecin: spectroscopic and molecular modeling studies. Mol Biol Rep
39:5115–5123. doi:10.1007/s11033-011-1307-z
36. Vis AN, Van der Gaast A, Van Rhijn BWG et al (2002) A phase II trial of methotrexatehuman serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who
progressed under immunotherapy. Cancer Chemother Pharmacol 49:342–345. doi:10.1007/
s00280-001-0417-z
37. Akdogan Y, Wu Y, Eisele K et al (2012) Host–guest interactions in polycationic human
serum albumin bioconjugates. Soft Matter 8:11106. doi:10.1039/c2sm26511g
38. Kitchens KM, Kolhatkar RB, Swaan PW, Ghandehari H (2008) Endocytosis inhibitors
prevent poly(amidoamine) dendrimer internalization and permeability across Caco-2 cells.
Mol Pharm 5:364–369. doi:10.1021/mp700089s
39. Kitchens KM, Foraker AB, Kolhatkar RB et al (2007) Endocytosis and interaction of poly
(amidoamine) dendrimers with Caco-2 cells. Pharm Res 24:2138–2145. doi:10.1007/s11095007-9415-0
40. Kuan SL, Sto ¨ckle B, Reichenwallner J et al (2013) Dendronized albumin core-shell transporters
with high drug loading capacity. Biomacromolecules 14:367–376. doi:10.1021/bm301531c
41. Wu Y, Pramanik G, Eisele K, Weil T (2012) Convenient approach to polypeptide copolymers
derived from native proteins. Biomacromolecules 13:1890–1898. doi:10.1021/bm300418r
42. Wu Y, Weil T (2012) An efficient approach for preparing giant polypeptide triblock
copolymers by protein dimerization. Macromol Rapid Comm 33:1304–1309. doi:10.1002/
marc.201200111
232
J. Hedrich et al.
aggrecan, the large aggregating proteoglycan from cartilage. Eur J Clin Chem Clin Biochem
32:249–257
23. Yin M, Ding K, Gropeanu RA et al (2008) Dendritic star polymers for efficient DNA binding
and stimulus-dependent DNA release. Biomacromolecules 9:3231–3238. doi:10.1021/
bm800797j
24. Ng JF, Jaenicke S, Eisele K et al (2010) cBSA-147 for the preparation of bacterial biofilms in
a microchannel reactor. Biointerphases 5:FA41–FA47. doi:10.1116/1.3474475
25. Ritz S, Eisele K, Dorn J et al (2010) Cationized albumin-biocoatings for the immobilization
of lipid vesicles. Biointerphases 5:FA78–FA87. doi:10.1116/1.3494039
26. Ng JF, Weil T, Jaenicke S (2011) Cationized bovine serum albumin with pendant RGD
groups forms efficient biocoatings for cell adhesion. J Biomed Mater Res B Appl Biomater
99:282–290. doi:10.1002/jbm.b.31897
27. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer
chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent
smancs. Cancer Res 46:6387–6392
28. Kratz F (2002) Drug conjugates with albumin and transferrin. Expert Opin Ther Pat
12:433–439. doi:10.1517/13543776.12.3.433
29. Maeda H (2001) The enhanced permeability and retention (EPR) effect in tumor vasculature:
the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul
41:189–207
30. Elsadek B, Kratz F (2012) Impact of albumin on drug delivery – new applications on the
horizon. J Control Release 157:4–28. doi:10.1016/j.jconrel.2011.09.069
31. Neumann E, Frei E, Funk D et al (2010) Native albumin for targeted drug delivery. Expert
Opin Drug Deliv 7:915–925. doi:10.1517/17425247.2010.498474
32. Varshney A, Sen P, Ahmad E et al (2010) Ligand binding strategies of human serum albumin:
how can the cargo be utilized? Chirality 22:77–87. doi:10.1002/chir.20709
33. Paa ´l K, Mu ¨ller J, Hegedu ˆs L (2001) High affinity binding of paclitaxel to human serum
albumin. Eur J Biochem 268:2187–2191
34. Xu R, Fisher M, Juliano RL (2011) Targeted albumin-based nanoparticles for delivery of
amphipathic drugs. Bioconjug Chem 22:870–878. doi:10.1021/bc1002295
35. Sun H-H, Zhang J, Zhang Y-Z et al (2012) Interaction of human serum albumin with
10-hydroxycamptothecin: spectroscopic and molecular modeling studies. Mol Biol Rep
39:5115–5123. doi:10.1007/s11033-011-1307-z
36. Vis AN, Van der Gaast A, Van Rhijn BWG et al (2002) A phase II trial of methotrexatehuman serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who
progressed under immunotherapy. Cancer Chemother Pharmacol 49:342–345. doi:10.1007/
s00280-001-0417-z
37. Akdogan Y, Wu Y, Eisele K et al (2012) Host–guest interactions in polycationic human
serum albumin bioconjugates. Soft Matter 8:11106. doi:10.1039/c2sm26511g
38. Kitchens KM, Kolhatkar RB, Swaan PW, Ghandehari H (2008) Endocytosis inhibitors
prevent poly(amidoamine) dendrimer internalization and permeability across Caco-2 cells.
Mol Pharm 5:364–369. doi:10.1021/mp700089s
39. Kitchens KM, Foraker AB, Kolhatkar RB et al (2007) Endocytosis and interaction of poly
(amidoamine) dendrimers with Caco-2 cells. Pharm Res 24:2138–2145. doi:10.1007/s11095007-9415-0
40. Kuan SL, Sto ¨ckle B, Reichenwallner J et al (2013) Dendronized albumin core-shell transporters
with high drug loading capacity. Biomacromolecules 14:367–376. doi:10.1021/bm301531c
41. Wu Y, Pramanik G, Eisele K, Weil T (2012) Convenient approach to polypeptide copolymers
derived from native proteins. Biomacromolecules 13:1890–1898. doi:10.1021/bm300418r
42. Wu Y, Weil T (2012) An efficient approach for preparing giant polypeptide triblock
copolymers by protein dimerization. Macromol Rapid Comm 33:1304–1309. doi:10.1002/
marc.201200111
232
J. Hedrich et al.